What are the antiplatelet or anticoagulation recommendations after atrial septal defect (ASD) occluder placement?

Antiplatelet and Anticoagulation After ASD/VSD Occluder Placement

All patients undergoing ASD or VSD occluder placement should receive aspirin 100 mg daily for at least 6 months after device implantation, with procedural anticoagulation using unfractionated heparin at the time of device deployment. 1, 2

---

Procedural Anticoagulation (At Time of Device Implantation)

• Administer unfractionated heparin 100 U/kg (maximum 5000 U) intravenously at the time of occluder deployment for both ASD and VSD closure 1, 2
• This is a Class I recommendation with Level of Evidence C 1

---

Post-Procedural Antiplatelet Therapy

Standard Regimen for ASD Occluder

• Aspirin 100 mg daily for minimum 6 months after device implantation (Class I, Level of Evidence C) 1, 2
• For older children and adults, consider adding an anticoagulant (such as a DOAC) in addition to aspirin for 3-6 months (Class IIb, Level of Evidence C) 1, 2

Standard Regimen for VSD Occluder

• Aspirin (low-dose) for at least 6 months after device implantation (Class IIa, Level of Evidence C) 1, 2
• The evidence for VSD closure is slightly less robust than for ASD, but the same duration is recommended 1

Alternative Dual Antiplatelet Regimen

• Some centers use aspirin plus clopidogrel 75 mg for 6-8 weeks, followed by aspirin alone for an additional 4-8 months 3
• Research shows both single and dual antiplatelet approaches are effective, with no thrombus formation detected in patients receiving clopidogrel plus aspirin 4

---

Duration Rationale and Extended Therapy Considerations

Why 6 Months?

• Complete device endothelialization requires approximately 6 months, which is the biological basis for this duration 1, 2
• Nickel release from Amplatzer devices peaks during the first 6 weeks and returns to baseline by 4-6 months, coinciding with neointima formation 5
• Coagulation activation (measured by prothrombin fragment F1+2) peaks at 7 days post-procedure and normalizes by 90 days 6

When to Extend Beyond 6 Months

• If residual shunt persists after device implantation, continue thromboprophylaxis beyond 6 months due to ongoing risk of paradoxical embolus 1, 2
• Greater coagulation activation occurs with residual shunts (r=0.53, p=0.050) 6

---

High-Risk Patient Modifications

Screening for Thrombophilic Disorders

• Exclude inherited thrombophilic disorders before device implantation in patients with history of stroke or thrombotic events 2, 3
• Adapt antithrombotic prophylaxis accordingly if thrombophilia is identified 2

Patients with Atrial Fibrillation

• If the patient has atrial fibrillation requiring anticoagulation, use oral anticoagulation (DOAC preferred) instead of or in addition to antiplatelet therapy based on stroke risk 1
• This represents a different clinical scenario than isolated structural heart defect closure 1

---

Monitoring and Follow-Up

• Perform transesophageal echocardiography within the first 4 weeks after implantation to detect early thrombus formation 3
• If thrombus is detected, extend antithrombotic regimen to avoid surgical device explantation 3
• Device thrombosis occurs in 0-10% of cases despite prophylaxis 3

---

Critical Pitfalls to Avoid

• Do not omit procedural heparin at the time of device deployment—this is a Class I recommendation 1, 2
• Do not discontinue aspirin before 6 months unless compelling contraindications exist, as complete endothelialization requires this duration 2, 5
• Do not assume complete closure eliminates thrombotic risk—residual shunts require extended prophylaxis 1, 2
• Do not use antiplatelet therapy alone in patients with atrial fibrillation—these patients require oral anticoagulation for stroke prevention 1

---

Evidence Quality Note

The evidence supporting these recommendations is primarily Level C (expert consensus and observational data), as no randomized controlled trials have compared antiplatelet regimens after occluder placement 3. However, the extremely low incidence of device thrombosis (when standard prophylaxis is used) supports the current approach 1, 4. Research shows no detectable platelet activation despite significant coagulation activation, raising questions about whether anticoagulants might be superior to antiplatelet agents 6, but current guidelines uniformly recommend aspirin-based regimens 1, 2.